OBJECTIVE. Particulate emboli are passive agents that follow blood flow. Deployed antireflux devices obstruct blood flow. CONCLUSION. The aim of this review is to describe the complex hemodynamic alterations to blood flow caused by the deployment of antireflux devices and the resulting changes to embolic distribution. The therapeutic goal is optimization of embolization safety and efficacy.
Bibliographical noteFunding Information:
S. C. Rose is a consultant for and serves on the scientific advisory board of Surefire Medical, is a proctor for and stockholder of Sirtex Medical, and is a consultant for Embolx Medical, Guerbet, XLSciTech, and Merit Medical. A. J. Isaacson is a speaker and consultant for Embolx Medical, has received research support from Boston Scientific, is a consultant for and has received research support from BTG, is a speaker and consultant for Terumo Medical, and is a consultant for Cook Medical. A. M. Fischman is a consultant for Surefire Medical; serves on the advisory board of Embolx Medical; is a consultant, member of the advisory board, and speaker for Terumo Medical; is a speaker for and has received research support and royalties from Merit Medical; is a speaker for Boston Scientific and BTG; and is an investor in Adient Medical. J. Golzarian is a consultant for Medtronic, Boston Scientific, Penumbra, and BTG and is a stockholder of Embomedics. We thank John Layton, Olivia Hernandez, Collin Hamill, and Tyler Badilla for their assistance in manuscript preparation.
© American Roentgen Ray Society.
- Antireflux devices
- Embolic distribution
- Hemodynamic alterations
- Particulate emboli
- Temporary balloon occlusion
- Transarterial chemoembolization
- Transarterial radioembolization